ChromaDex Reports Record Revenue as Ingredients Sales Climb 83% Compared to Previous Year Period
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
ChromaDex (CDXC) Receives FDA GRAS No Objection Letter for NIAGEN
August 15, 2016 6:32 AM EDTChromaDex Corp. (Nasdaq: CDXC) announced that the U.S. Food and Drug Administration (FDA) has issued a generally recognized as safe (GRAS) No Objection Letter, in response to the NIAGEN® nicotinamide riboside chloride (NR) GRAS filing, Notice No. GRN 000635.
Receipt of... More
ChromaDex (CDXC) Reports Q2 EPS of $0.00
August 11, 2016 4:41 PM EDTChromaDex (NASDAQ: CDXC) reported Q2 EPS of $0.00, versus ($0.01) reported last year. Revenue for the quarter came in at $8.8 million, versus $6.1 million reported last year.
For earnings history and earnings-related data on ChromaDex (CDXC) click here.
... More